{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.9","upperLimit":"58.7","value":"46.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Overall survival was defined as the time from brexucabtagene autoleucel infusion to the date of death from any cause. Overall survival was determined using the KM estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants from the mITT Analysis Set in Cohort 1 were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 7.8 years","title":"Overall Survival in Cohort 1","type":"SECONDARY","unitOfMeasure":"months"}